Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost drugs come to the market.
And while the United States does not have the same cost constraints as the single-payer health systems, it too faces heightened pressures to lower costs in order to afford innovative therapies.
At the 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, Omar Ali, University of Portsmouth, said that, in Europe, high-cost drugs to treat hepatitis C marked a turning point at which payers realised that promising cures were hollow victories if using them came at too high a price for the health system to afford. The United States, he added, is following suit, with the Institute for Clinical and Economic Review (ICER) gaining traction with its health technology assessments.
